Expanding Therapeutic Horizons: Targeting Non-V600 BRAF Mutations in Solid Tumors

In this commentary, an expert addresses the importance of targeting non-V600 BRAF alterations in cancer and the emerging data on investigational agents targeting these alterations in patients.

Share

Program Content

Activities

Class II and III BRAF Alterations in Cancer
Expanding Therapeutic Horizons: Targeting Non-V600 BRAF Mutations in Solid Tumors
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: August 02, 2023

Faculty

cover img faculity

Alexander Spira, MD, PhD, FACP

Director                                                                                                                                                                        NEXT Oncology Virginia
Clinical Assistant Professor
Johns Hopkins
Co-Director                                                                                                                                                                    Clinical Research
Virginia Cancer Specialists
Fairfax, Virginia

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Kinnate Biopharma.

Kinnate Biopharma